

IntelGenx Technologies Corp.  
Form 8-K  
May 21, 2014

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**Current Report  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**May 21, 2014**  
Date of Report (Date of Earliest Event Reported)

**IntelGenx Technologies Corp.**  
(Exact Name of Registrant as Specified in its Charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**000-31187**  
(Commission File  
Number)

**870638336**  
(IRS Employer Identification  
No.)

**6425 Abrams, Ville St- Laurent, Quebec, Canada**  
(Address of principal executive offices)

**H4S 1X9**  
(Zip Code)

Registrant's telephone number, including area code: (514) 331-7440

Check the appropriate box below if the Form 8K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 8.01 Other Events - News Release**

**IntelGenx and RedHill Biopharma Report Positive Bioavailability Study Results in Support of Planned European Marketing Application in Q3/2014 for Anti-Migraine VersaFilm Product**

Exhibit	Description
<u>99.1</u>	<u>Press Release</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**INTELGENX TECHNOLOGIES CORP.**

Dated: May 21, 2014

By:

*/s/ Rajiv Khosla*

Rajiv Khosla

President and Chief Executive Officer

---